Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 63 results found. Search for [ pfizer vaccine India rollout ]

Results 40 to 60 of 63
BusinessToday.In
December 18, 2020
COVID-19 vaccine will be introduced only when the safety is proven. As is true for other vaccines, the common side effects in some individuals could be mild fever, pain, etc. at the site of injection, said the ministry


Reuters
December 18, 2020
If India received a lower allocation of 95-125 million doses via COVAX, then the cost to the government of procuring additional shots would go up to $1.8 billion


BusinessToday.In
December 15, 2020
A senior official from WHO told Reuters about its talks with both companies to include their coronavirus vaccines as part of an early global rollout


BusinessToday.In
December 14, 2020
India Stock Market Highlights Today: ONGC followed by Tata Steel, L&T, Sun Pharma, M&M, ICICI Bank and NTPC were among the top gainers in the Sensex pack


Reuters
December 13, 2020
The deal comes in a week that AstraZeneca said it was conducting further research to confirm whether its COVID-19 vaccine could be 90% effective, potentially slowing its rollout, and as a rival shot from Pfizer was launched in Britain and approved for use in the United States


BusinessToday.In
December 11, 2020
GSK said phase 1/2 interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years but there was an insufficient response in older adults


BusinessToday.In
December 10, 2020
India Stock Market Highlights Today: UltraTech Cement followed by Tata Steel, ONGC, IndusInd Bank, HDFC Bank, M&M, Infosys and Reliance Industries were among the top losers in the Sensex pack. On the other hand, Maruti, Nestle India, Titan and PowerGrid were among the gainers


BusinessToday.In
December 9, 2020
India Stock Market Highlights Today: Intraday, both indices touched all time highs today, with Sensex hitting 46,164 and Nifty touching 13,548.


BusinessToday.In
December 7, 2020
On December 2, the UK became the first nation to approve Pfizer-BioNTech vaccine against COVID-19 for emergency use; Bahrain has also approved vaccine candidate 'BNT162b2'. India decision on vaccine could come this week


PTI
December 7, 2020
Patients aged 80 and above who are already attending hospital as an outpatient, and those who are being discharged home after a hospital stay, will be among the first to receive the \"life-saving jab\"


BusinessToday.In
December 6, 2020
Pfizer Inc submitted application to DCGI seeking emergency use authorisation on Dec 4; also seeks permission to import vaccine for sale and distribution in India


BusinessToday.In
December 5, 2020
On December 2, the UK became the first country in the world to approve Pfizer and BioNTech coronavirus candidate BNT162b2 after the Medicines and Healthcare Products Regulatory Agency found the jab safe for widespread rollout


Reuters
December 5, 2020
WHO's top emergency expert Mike Ryan also cautioned against complacency in the wake of vaccine roll-out, adding although they were a major part of the battle against COVID-19, vaccines would not on their own end the pandemic


BusinessToday.In
December 4, 2020
Study says anti-bodies declined slightly over time but remained elevated in all participants even 3 months after vaccination. NIAID director Anthony Fauci and other infectious diseases experts say it is possible that our bodies would remember virus and produce more anti-bodies if exposed to the virus again


Aseem Thapliyal
December 3, 2020
Sensex rose 335 points to 44,953 against previous close of 44,618. Nifty too climbed 103 points to 13,216 against previous close of 13,113


Manoj Sharma
December 2, 2020
Pfizer and BioNTech vaccine: The UK has already ordered 40 million doses of the Pfizer vaccine to vaccinate its 20 million population, of which around 10 million doses will be available soon


BusinessToday.In
November 29, 2020
As coronavirus cases continue to rise, the UK plans to move fast in the approval process and clearance to Pfizer and BioNTech SE could come by next week


BusinessToday.In
November 24, 2020
Vardhan says it makes no sense to consider Pfizer as pharma major is yet to get approval in the US. After requisite approvals, US pharma major will have to cater to needs of its own country's population first


Manoj Sharma
November 18, 2020
Pfizer says Phase 3 study of their COVID-19 vaccine candidate met \"all primary efficacy endpoints\".  During its early analysis, vaccine had shown 90 per cent efficacy but final analysis involving 170 confirmed cases of COVID-19 showed 95 per cent efficacy


BusinessToday.In
November 3, 2020
German biotech firm CureVac has revealed its vaccine candidate has triggered an immune response during its phase 1 trials. The UK government has also started the process of the rolling review of AstraZeneca's candidate


PAGES 3 OF 4  1234